These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23379766)

  • 21. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia.
    Lim HF; Phua J; Mukhopadhyay A; Ngerng WJ; Chew MY; Sim TB; Kuan WS; Mahadevan M; Lim TK
    Eur Respir J; 2014 Mar; 43(3):852-62. PubMed ID: 24176994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia.
    Phua J; See KC; Chan YH; Widjaja LS; Aung NW; Ngerng WJ; Lim TK
    Thorax; 2009 Jul; 64(7):598-603. PubMed ID: 19386583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
    Ott SR; Hauptmeier BM; Ernen C; Lepper PM; Nüesch E; Pletz MW; Hecht J; Welte T; Bauer TT
    Eur Respir J; 2012 Mar; 39(3):611-8. PubMed ID: 21965229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.
    Kontou P; Kuti JL; Nicolau DP
    Am J Emerg Med; 2009 Oct; 27(8):968-74. PubMed ID: 19857416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
    Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
    Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
    Martínez JA; Horcajada JP; Almela M; Marco F; Soriano A; García E; Marco MA; Torres A; Mensa J
    Clin Infect Dis; 2003 Feb; 36(4):389-95. PubMed ID: 12567294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
    Murcia JM; González-Comeche J; Marín A; Barberán J; Granizo JJ; Aguilar L; González-Moreno J; González-Pina B; López-Dupla M; Irurzun J;
    Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ; Arnold C; Bassetti S
    Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.
    Martin-Loeches I; Lisboa T; Rodriguez A; Putensen C; Annane D; Garnacho-Montero J; Restrepo MI; Rello J
    Intensive Care Med; 2010 Apr; 36(4):612-20. PubMed ID: 19953222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
    Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
    Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
    Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
    Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
    Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
    Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.